^
Association details:
Biomarker:EGFR S768I
Cancer:Non Small Cell Lung Cancer
Drug:gefitinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
03/16/2022
Excerpt:
The NCCN NSCLC Panel has preference stratified the systemic therapy regimens and decided that afatinib or osimertinib are preferred options for patients with metastatic NSCLC and EGFR L861Q, G719X, and S768I mutation; other recommended options include erlotinib, gefitinib, dacomitinib.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

145P-UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations

Published date:
03/17/2021
Excerpt:
Uncommon mutation categories were: major uncommon (G719X, L861Q, S768I; 73%); compound (35%); ex20ins (12%); T790M (7%); other (9%). Most pts (n = 226; 92%) were treated in 1st-line with an EGFR TKI; 132 (54%), 70 (28%), 35 (14%) and 7 (3%) received afatinib, gefitinib, erlotinib and osimertinib....Overall median OS was 24.4 mos....ORR was 42% overall (major: 50%; compound: 49%; other: 44%; T790M: 20%; ex20ins: 17%); afatinib: 44% (DoR: 12.0 mos); 1st-gen TKIs: 44% (DoR: 11.0 mos)....Response was highest in pts with major uncommon, and/or compound mutations.
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

Excerpt:
Response to treatment was analyzed in three major groups: (i) uncommon mutations (G719X, S7681, L861Q and combinations)....In patients with uncommon EGFR mutations (group 1), median PFS (mPFS) was significantly longer when patients were treated with EGFR-TKI in 1L compared to chemotherapy (HR 0.53; 95% CI 0.30-0.93, P = 0.028…. Afatinib was the most frequently applied EGFR-TKI in this group (36/79 treatments, 46%), followed by erlotinib (22/79 treatments, 28%), gefitinib (13/79 treatments, 16%) and osimertinib (8/79 treatments, 10%) (Figure 3A).
DOI:
https://doi.org/10.1016/j.annonc.2022.02.225
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I)

Excerpt:
We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib.
DOI:
10.1093/jjco/hyq087
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

Excerpt:
CONTRADICTING EVIDENCE: Cells expressing S768I and E709G mutant were actually more resistant to gefitinib than cells expressing the wild-type receptor…
DOI:
10.1038/sj.onc.1209159